ClinicalTrials.gg

Program

BC008-1A

A development code. Also written as “BC008-1A 900mg” and “BC008-1A 1200mg”.

Its studies are mostly in Glioblastoma · Esophageal Neoplasms, led by Sichuan Luzhou Buchang Biopharmaceutical.

Furthest: phase 1, since Jan 2, 20252 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Luzhou Buchang Biopharmaceutical22 open or runningphase 1since Jan 2, 2025Jan 2, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 2, 2025First studies: 2 phase 1 studiesFirst studyNCT06773507, NCT06773481

TargetBeta

TIGIT →read by rule
“BC008-1A is an innovative bispecific antibody targeting TIGIT and PD-1, which is developed by Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.”study text, by rule · the study

Other programs on TIGIT

ProgramCompanyFurthest phaseStudies
rilvegostomigAstraZenecaphase 324
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
domvanalimabruleGilead Sciencesphase 310

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06773507Esophageal Neoplasms · China1RecruitingJun 202680
NCT06773481Glioma · China1RecruitingJun 202640

How it is read

Names in the registry

  • “BC008-1A”, 2 entries
  • “BC008-1A 900mg”, 1 entry
  • “BC008-1A 1200mg”, 1 entry

Codes read as this program: BC0081A.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.